Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)

被引：23

作者：

Ziemssen T. ^{[1
]}

Sylvester L. ^{[2
]}

Rametta M. ^{[2
]}

Ross A.P. ^{[3
]}

机构：

[1] Department of Neurology, Centre for Clinical Neurosciences, University Hospital Carl Gustav Carus at the Technical University of Dresden, Dresden

[2] Bayer HealthCare Pharmaceuticals, Whippany, NJ

[3] Loyola University Chicago, Maywood, IL

来源：

Neurology and Therapy | 2015年 / 4卷 / 2期

关键词：

Beta-interferons; Disease-modifying therapies; Electronic autoinjector; Patient survey; Relapsing–remitting multiple sclerosis;

D O I：

10.1007/s40120-015-0036-y

中图分类号：

学科分类号：

摘要：

Introduction: Multiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia—but these can be addressed by improvements in autoinjector design. The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer Pharma AG), a novel interferon beta-1b autoinjector. Methods: Patients in Germany performing self-injections using BETACONNECT took part in the study. Data were collected through an online 15-min structured survey. Participants rated their experience with BETACONNECT on a 6-point scale and those satisfied with BETACONNECT were asked to describe the reason using a free-text box. Results: One-hundred and eighteen patients with MS completed the survey. Ninety percent preferred BETACONNECT to their previous injection method (only 4% previously used manual injections, so most had previously used other autoinjectors). Ninety-two percent were very confident/confident in their ability to perform an injection using BETACONNECT. The most common free-text responses to “Why are you satisfied with the BETACONNECT™ autoinjector?” were ease of use (46%), less irritation/pain at the injection site (33%), and smoother injections (24%). Features considered most useful were automated injections (98%), adjustable injection speed (98%), and adjustable injection depth (98%). Ninety-seven percent thought it was easy to know when an injection was complete and 95% agreed/strongly agreed it was easy to learn to use the autoinjector. Seventy-three percent agreed that the quietness and effortlessness of the BETACONNECT reduced their level of injection anxiety, 92% that its size and shape makes it easy to handle during injections, and 67% that it decreases injection site pain. Eighty percent of those using the reminder function thought they were less likely to miss an injection. Conclusion: Patients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients’ overall injection experience. Funding: Bayer HealthCare Pharmaceuticals. © 2015, The Author(s).

引用

页码：125 / 136

页数：11

共 29 条

[1]

Atlas of MS 2013: mapping multiple sclerosis around the world., (2013)

[2]

Degenhardt A., Ramagopalan S.V., Scalfari A., Ebers G.C., Clinical prognostic factors in multiple sclerosis: a natural history review, Nat Rev Neurol., 5, 12, pp. 672-682, (2009)

[3]

Weinshenker B.G., Bass B., Rice G.P.A., Et al., The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability, Brain., 112, 1, pp. 133-146, (1989)

[4]

Plosker G.L., Interferon-β-1b: a review of its use in multiple sclerosis, CNS Drugs., 25, 1, pp. 67-88, (2011)

[5]

Mikol D., Lopez-Bresnahan M., Taraskiewicz S., Et al., A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis, Mult Scler., 11, 5, pp. 585-591, (2005)

[6]

Brochet B., Lemaire G., Beddiaf A., Et al., Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices, Rev Neurol (Paris)., 162, 6-7, pp. 735-740, (2006)

[7]

Lugaresi A., Rottoli M.R., Patti F., Fostering adherence to injectable disease-modifying therapies in multiple sclerosis, Expert Rev Neurother, 14, 9, pp. 1029-1042, (2014)

[8]

Pozzilli C., Schweikert B., Ecari U., Et al., Supportive strategies to improve adherence to IFN beta-1b in multiple sclerosis—results of the BetaPlus observational cohort study, J Neurol Sci, 307, pp. 120-126, (2011)

[9]

Lugaresi A., Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?, Expert Opin Drug Deliv, 6, 9, pp. 995-1002, (2009)

[10]

Phillips J.T., Fox E., Grainger W., Tuccillo D., Liu S., Deykin A., An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex<sup>®</sup> prefilled syringe in multiple sclerosis subjects, BMC Neurol., 11, (2011)

← 1 2 3 →